Navamedic — Earnings Release 2015

Feb 18, 2016

Strong sales - product launch affected profitability

Strong sales - product launch affected profitability

Navamedic ASA today announced the Company's fourth quarter and full year 2015

financial results. The Company's sales reach all time high levels both in the

quarter and for the year, while profitability was affected by the introduction

of Navamedic's new product Sippi.

Navamedic posted sales of NOK 65.4 million in the fourth quarter, compared to

NOK 61.9 million in the last quarter of 2014. EBITDA for the quarter ended at

NOK -0.1 million, compared to NOK 5.3 million the previous year. The Company's

net result for the quarter came in at NOK -10.9 million, against NOK -2.2

million if the fourth quarter of 2014.

The reduction in Navamedic's profitability is mainly caused by the international

launch of the Company's new urine monitoring system for intensive care patients,

Sippi. The new product was launched in the third quarter, and was during the

fourth quarter introduced in additional markets. Sippi is currently in test use

by hospitals across nine European countries, and is expected to start generating

revenues in 2016.

For the full year 2015, Navamedic had sales of NOK 248.3 million, which an 11

per cent increase from 2014. Affected by the acquisition of Observe Medical and

the launch of its product Sippi, Navamedic's EBITDA ended at NOK 8.8 million,

compared to the 2014 EBITDA of NOK 15.7 million. Net result for 2015 was NOK

-10.9 million, against NOK -0.7 the previous year.

Going forward, Navamedic expects continued sales growth for its Nordic pharma

and healthcare business. The Company's main priority in this business remains

margin improvements. The new product Sippi is a potential game changer in the

monitoring fluid balance in seriously ill patients. In parallel with the

introduction of Sippi in additional markets, extensive product development is

ongoing. During 2016, Sippi will be able to upload patient data automatically

into the hospital's data system

For further information, please contact CEO Tom Rönnlund, telephone

+46 727 320 321

Navamedic ASA is a Norwegian medtech and pharmaceutical products

company,delivering products to patients, hospitals and pharmacies in the Nordic

and Benelux markets. The Group's Medtech business has developed and is currently

introducing the next generation digital urine meter Sippi ®. Navamedic's Pharma

and Healthcare business is a distributor of products supplied by a number of

pharmaceutical manufacturers. Navamedic is listed on the Oslo Stock

Exchange(ticker: NAVA).

www.navamedic.com

This information is subject of the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act

[HUG#1987105]